News Quantified

IPSEY – ipsen sa s/adr (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Origami Therapeutics Announces Global Collaboration with Ipsen to Advance Protein Degrader Program

Ipsen nominates Peter Guenter to its Board of Directors

Pierrick Lefranc appointed as Executive Vice President Technical Operations, member of Executive Leadership Team

Arbitration tribunal upholds Ipsen’s termination of R&D agreement with Galderma

U.S. FDA grants Ipsen’s IPN60340 (ICT01) Breakthrough Therapy Designation in first line unfit Acute Myeloid Leukemia

Top News Gainers

4/20 Ipsen Announces Positive Topline Results From Pivotal Phase III CheckMate -9ER Trial Evaluating CABOMETYX® (cabozantinib) in Combination with Opdivo® (nivolumab) in Previously Untreated Advanced Renal Cell Carcinoma 5.8%

4/22 Ipsen Reports Solid Sales Growth in First Quarter 2020 With Limited COVID-19 Impact 5.5%

4/27 Photocure Regains Worldwide Rights of Hexvix 3.8%

5/20 IPSEN S A/S (OTCMKTS: IPSEY) was upgraded by analysts at JPMorgan Chase & Co. from an "underweight" rating to a "neutral" rating. 1.9%

7/23 Ipsen: Disclosure of Transactions in Own Shares Between 15/07/2019 And 19/07/2019 1.8%

5/28 Combined Shareholders’ Meeting of IPSEN S.A. held on 28 May 2019 1.3%

4/1 Ipsen Donates €2 Million to the Institut Pasteur to Support Research on COVID-19 1.2%

4/14 Ipsen: Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company 1.0%

6/17 IPSEN: Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company 1.0%

5/13 IPSEN: Monthly information regarding the total number of voting rights and total number of shares of the Company 1.0%

Top News Decliners

1/24 Ipsen’s palovarotene clinical program in fibrodysplasia ossificans progressiva reaches prespecified interim analysis futility criteria -23.2%

12/6 Ipsen Initiates Partial Clinical Hold for Palovarotene IND120181 and IND135403 Studies -13.7%

7/28 Ipsen S.A. ADR (IPSEY) CEO David Meek on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha] -6.0%

1/9 IPSEN S A/S (OTCMKTS: IPSEY) was downgraded by analysts at Jefferies Financial Group Inc from a "buy" rating to a "hold" rating. -5.2%

12/18 Ipsen Announces Departure of David Meek as Chief Executive Officer -5.1%

12/6 Ipsen Plunges as FDA Halts Bone Drug Trial in Children on Safety Concerns [Yahoo! Finance News] -5.0%

3/3 IPSEN S A/S (OTCMKTS: IPSEY) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -4.6%

2/13 Ipsen Presents Its 2019 Results, Provides 2020 Guidance and Updates 2022 Financial Outlook -4.2%

3/11 Ipsen Data Presented during ENETS Annual Conference 2020 Capture New Patient and Healthcare Professional Insights in the Treatment of NETs and Acromegaly -2.9%

3/17 Ipsen: Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company -2.7%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day